The economics of coeliac disease

A population-based study

K. H. Long, A. Rubio-Tapia, A. E. Wagie, L. J. Melton, B. D. Lahr, C. T. Van Dyke, Joseph A Murray

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background Despite increasing prevalence, the economic implications of coeliac disease are just emerging. Aims To assess the impact of coeliac disease diagnosis on healthcare costs and the incremental costs associated with coeliac disease. Methods Administrative data for a population-based cohort of coeliac disease cases and matched controls from Olmsted County, Minnesota were used to compare (i) direct medical costs 1 year pre- and post-coeliac disease diagnosis for 133 index cases and (ii) 4-year cumulative direct medical costs incurred by 153 index cases vs. 153 controls. Analyses exclude diagnostic-related and out-patient pharmaceutical costs. Results Average total costs were reduced by $1764 in the year following diagnosis (pre-diagnosis cost of $5023 vs. $3259; 95% CI of difference: $688 to $2993). Over a 4-year period, coeliac disease cases experienced higher out-patient costs (mean difference of $1457; P = 0.016) and higher total costs than controls (mean difference of $3964; P = 0.053). Excess average total costs were concentrated among males with coeliac disease ($14 191 vs. $4019 for male controls; 95% CI of difference: $2334 to $20 309). Conclusions Coeliac disease-associated costs indicate a significant economic burden of disease, particularly for diseased males. Diagnosis and treatment of coeliac disease reduce medical costs of care suggesting an economic advantage to earlier detection and treatment.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume32
Issue number2
DOIs
StatePublished - Jul 15 2010

Fingerprint

Celiac Disease
Economics
Costs and Cost Analysis
Population
Cost of Illness
Health Care Costs
Outpatients
Cost Control
Abdomen

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Long, K. H., Rubio-Tapia, A., Wagie, A. E., Melton, L. J., Lahr, B. D., Van Dyke, C. T., & Murray, J. A. (2010). The economics of coeliac disease: A population-based study. Alimentary Pharmacology and Therapeutics, 32(2), 261-269. https://doi.org/10.1111/j.1365-2036.2010.04327.x

The economics of coeliac disease : A population-based study. / Long, K. H.; Rubio-Tapia, A.; Wagie, A. E.; Melton, L. J.; Lahr, B. D.; Van Dyke, C. T.; Murray, Joseph A.

In: Alimentary Pharmacology and Therapeutics, Vol. 32, No. 2, 15.07.2010, p. 261-269.

Research output: Contribution to journalArticle

Long, KH, Rubio-Tapia, A, Wagie, AE, Melton, LJ, Lahr, BD, Van Dyke, CT & Murray, JA 2010, 'The economics of coeliac disease: A population-based study', Alimentary Pharmacology and Therapeutics, vol. 32, no. 2, pp. 261-269. https://doi.org/10.1111/j.1365-2036.2010.04327.x
Long KH, Rubio-Tapia A, Wagie AE, Melton LJ, Lahr BD, Van Dyke CT et al. The economics of coeliac disease: A population-based study. Alimentary Pharmacology and Therapeutics. 2010 Jul 15;32(2):261-269. https://doi.org/10.1111/j.1365-2036.2010.04327.x
Long, K. H. ; Rubio-Tapia, A. ; Wagie, A. E. ; Melton, L. J. ; Lahr, B. D. ; Van Dyke, C. T. ; Murray, Joseph A. / The economics of coeliac disease : A population-based study. In: Alimentary Pharmacology and Therapeutics. 2010 ; Vol. 32, No. 2. pp. 261-269.
@article{96796ac9f3224990978de6e5dcefe960,
title = "The economics of coeliac disease: A population-based study",
abstract = "Background Despite increasing prevalence, the economic implications of coeliac disease are just emerging. Aims To assess the impact of coeliac disease diagnosis on healthcare costs and the incremental costs associated with coeliac disease. Methods Administrative data for a population-based cohort of coeliac disease cases and matched controls from Olmsted County, Minnesota were used to compare (i) direct medical costs 1 year pre- and post-coeliac disease diagnosis for 133 index cases and (ii) 4-year cumulative direct medical costs incurred by 153 index cases vs. 153 controls. Analyses exclude diagnostic-related and out-patient pharmaceutical costs. Results Average total costs were reduced by $1764 in the year following diagnosis (pre-diagnosis cost of $5023 vs. $3259; 95{\%} CI of difference: $688 to $2993). Over a 4-year period, coeliac disease cases experienced higher out-patient costs (mean difference of $1457; P = 0.016) and higher total costs than controls (mean difference of $3964; P = 0.053). Excess average total costs were concentrated among males with coeliac disease ($14 191 vs. $4019 for male controls; 95{\%} CI of difference: $2334 to $20 309). Conclusions Coeliac disease-associated costs indicate a significant economic burden of disease, particularly for diseased males. Diagnosis and treatment of coeliac disease reduce medical costs of care suggesting an economic advantage to earlier detection and treatment.",
author = "Long, {K. H.} and A. Rubio-Tapia and Wagie, {A. E.} and Melton, {L. J.} and Lahr, {B. D.} and {Van Dyke}, {C. T.} and Murray, {Joseph A}",
year = "2010",
month = "7",
day = "15",
doi = "10.1111/j.1365-2036.2010.04327.x",
language = "English (US)",
volume = "32",
pages = "261--269",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The economics of coeliac disease

T2 - A population-based study

AU - Long, K. H.

AU - Rubio-Tapia, A.

AU - Wagie, A. E.

AU - Melton, L. J.

AU - Lahr, B. D.

AU - Van Dyke, C. T.

AU - Murray, Joseph A

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Background Despite increasing prevalence, the economic implications of coeliac disease are just emerging. Aims To assess the impact of coeliac disease diagnosis on healthcare costs and the incremental costs associated with coeliac disease. Methods Administrative data for a population-based cohort of coeliac disease cases and matched controls from Olmsted County, Minnesota were used to compare (i) direct medical costs 1 year pre- and post-coeliac disease diagnosis for 133 index cases and (ii) 4-year cumulative direct medical costs incurred by 153 index cases vs. 153 controls. Analyses exclude diagnostic-related and out-patient pharmaceutical costs. Results Average total costs were reduced by $1764 in the year following diagnosis (pre-diagnosis cost of $5023 vs. $3259; 95% CI of difference: $688 to $2993). Over a 4-year period, coeliac disease cases experienced higher out-patient costs (mean difference of $1457; P = 0.016) and higher total costs than controls (mean difference of $3964; P = 0.053). Excess average total costs were concentrated among males with coeliac disease ($14 191 vs. $4019 for male controls; 95% CI of difference: $2334 to $20 309). Conclusions Coeliac disease-associated costs indicate a significant economic burden of disease, particularly for diseased males. Diagnosis and treatment of coeliac disease reduce medical costs of care suggesting an economic advantage to earlier detection and treatment.

AB - Background Despite increasing prevalence, the economic implications of coeliac disease are just emerging. Aims To assess the impact of coeliac disease diagnosis on healthcare costs and the incremental costs associated with coeliac disease. Methods Administrative data for a population-based cohort of coeliac disease cases and matched controls from Olmsted County, Minnesota were used to compare (i) direct medical costs 1 year pre- and post-coeliac disease diagnosis for 133 index cases and (ii) 4-year cumulative direct medical costs incurred by 153 index cases vs. 153 controls. Analyses exclude diagnostic-related and out-patient pharmaceutical costs. Results Average total costs were reduced by $1764 in the year following diagnosis (pre-diagnosis cost of $5023 vs. $3259; 95% CI of difference: $688 to $2993). Over a 4-year period, coeliac disease cases experienced higher out-patient costs (mean difference of $1457; P = 0.016) and higher total costs than controls (mean difference of $3964; P = 0.053). Excess average total costs were concentrated among males with coeliac disease ($14 191 vs. $4019 for male controls; 95% CI of difference: $2334 to $20 309). Conclusions Coeliac disease-associated costs indicate a significant economic burden of disease, particularly for diseased males. Diagnosis and treatment of coeliac disease reduce medical costs of care suggesting an economic advantage to earlier detection and treatment.

UR - http://www.scopus.com/inward/record.url?scp=77953784644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953784644&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04327.x

DO - 10.1111/j.1365-2036.2010.04327.x

M3 - Article

VL - 32

SP - 261

EP - 269

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -